You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 282 No. 4, July 28, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Contempo 1999: Updates Linking Evidence and Experience
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (13)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Thrombolysis
 •Cardiovascular Intervention
 •Alert me on articles by topic

Anticoagulant-Induced Thrombosis

J. O. Ballard, MD

JAMA. 1999;282:310-312.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

Each year thromboembolism affects millions of individuals worldwide. As a result, anticoagulants are among the most commonly prescribed drugs in clinical practice. Heparin sodium and warfarin sodium are used alone or sequentially for primary and secondary prophylaxis in the management of a variety of thrombotic diseases. Bleeding complications associated with these agents are well-known; however, the risks and causes of paradoxical venous or arterial thrombosis occurring during anticoagulant therapy have only recently been elucidated. This article reviews the current understanding of serious acquired-prothrombotic states that can occasionally develop during treatment with anticoagulants. As background, a brief description of each drug's mechanism of action is first presented.


Anticoagulant Properties of Heparins and Warfarin

When given intravenously or subcutaneously, standard unfractionated heparin exerts its antithrombotic effect by first combining with antithrombin III, a native plasma inhibitor of coagulation. This interaction produces a conformational change that then dramatically enhances the efficiency with which antithrombin III . . . [Full Text of this Article]

Heparin-Induced Thrombocytopenia and Thrombosis

Coumarin Drugs and Thrombosis

Conclusions

Author Affiliation: Section of Hematology/Oncology, College of Medicine, Pennsylvania State University, Hershey.


RELATED ARTICLE

July 28, 1999
JAMA. 1999;282(4):399-400.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions
Cointault et al.
Nephrol Dial Transplant 2004;19:171-178.
ABSTRACT | FULL TEXT  

Patients with a History of Type II Heparin-Induced Thrombocytopenia with Thrombosis Requiring Cardiac Surgery with Cardiopulmonary Bypass: A Prospective Observational Case Series
Nuttall et al.
Anesth. Analg. 2003;96:344-350.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.